Providence (RI) Business News (6/7, Graham) reports the FDA has approved Tauvid (flortaucipir F 18 injection) “for use in the early diagnosis of Alzheimer’s disease.” Studies show Tauvid “used along with positron emission tomography, or PET, imaging, helps detect the presence of a substance known as tau protein in Alzheimers’s patients’ brains.” Rhode Island Hospital Alzheimer’s Disease and Memory Disorders Center Associate Director Dr.
Jonathan Drake said, “The announcement by the FDA regarding approval of tau-PET imaging for Alzheimer’s disease in the clinic is a major advancement for the field.”.